Exelixis announces results from dose-escalation stage of phase 1b COSMIC-021 study
Exelixis announced results from the dose-escalation stage of the phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in previously untreated advanced renal cell carcinoma (RCC). The findings demonstrate encouraging clinical activity for the combination. October 22, 2018